Comments
Long-term investors can buy the shares of Natco Pharma (₹629.35) at current levels. This stock has been in a strong downtrend since July 2021. The rise from the low of ₹502 made in February this year is giving a good sign of a trend reversal. This upmove began from a strong long-term trend line support poised around ₹500.
On the weekly chart, moving average cross-over is also strengthening the case for a trend reversal. These factors confirm that a new leg of a long-term rally in Natco Pharma’s stock has begun.
Immediate support is in the ₹605-595 region. Below that, ₹565 is the next important support zone. Resistance is in the ₹695-715 region. This can be tested in the next few weeks. A corrective fall from there will be short-lived and limited to ₹630.
Also read: Nifty marches towards new highs on frenzied investor buying
An eventual break above ₹715 will see Natco Pharma’s share price targeting ₹1,000 over the next year. That will also keep the doors open to test ₹1,200-1,300 by the end of 2024 or in early 2025.
Investors can buy now. Accumulate on dips at ₹595. Keep the stop-loss at ₹480. Trail the stop-loss up to ₹660 when the price moves up to ₹740. Move the stop-loss further up to ₹840 when Natco Pharma’s share price touches ₹1,020. Exit the stock at ₹1,200.
The bullish outlook will get negated only if the share price declines below ₹500. In that case, a fall to ₹380 can happen.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.